Omega-3-fatty Acids on Age-related Macular

Completed · Not applicable · Has a placebo group

Conditions studied: Aged Macular Degeneration

In brief

Aim: To demonstrate the short-term multi focal electroretinogram (mfERG) effect of oral omega-3-fatty acids in the triglyceride form on dry age-related macular degeneration (AMD). Null hypothesis: Omega-3-fatty acids do not affect the mfERGs of patients with dry AMD.

Key facts

Study ID

NCT01258335

Run by

Mid Atlantic Retina

People needed

25

Starts

2008-10-01

Expected to finish

2010-11-01

Last updated by the study team

2011-11-22

Who can join

Age: 20 and older, up to 49. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• i. >49 year old women and men for the dry AMD arms. >20 year old for the normal retina arm.
• No specific race/ethnic background requirements

You may not qualify if…

• i. For dry AMD groups, all patients will be included, regardless of prior or concomitant treatment, and regardless of stage of disease.
• ii. Patients already taking omega-3-fatty acids will be excluded. iii. Women of childbearing age with positive urine pregnancy tests or with plans to conceive during the six month study period will be excluded.

Where it is running

• Mid Atlantic Retina — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.